SCHEMBL5215708

SCHEMBL5215708

N=C(c1ccc(F)cc1)c1cccnc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 2/20 0.47
KMT2A Q03164 5/20 0.40
PRKCI P41743 2/20 0.40
DHODH Q02127 1/20 0.38
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
NPC1 O15118 3/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 4/20 0.36
MEN1 O00255 2/20 0.36
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5215013 0.83 NAPRT (0.47) NAPRTKMT2APRKCIMKNK1MKNK2
SCHEMBL28764683 0.81 ADRB2 (0.46) NAPRTPRKCIMKNK1MKNK2NPC1
SCHEMBL2679689 0.80 NAPRT (0.56) NAPRTKMT2APRKCIDHODHMKNK1
SCHEMBL5213334 0.80 NPC1 (0.48) NAPRTKMT2ANPC1RAB9AMEN1
SCHEMBL5211758 0.79 NAPRT (0.46) NAPRTPRKCIMKNK1MKNK2NOS3
SCHEMBL24061946 0.78 NAPRT (0.46) NAPRTPRKCILMNAPOLBALDH1A1
SCHEMBL5212527 0.75 GABRP (0.46) NAPRTKMT2APRKCIMKNK1MKNK2
SCHEMBL5215773 0.75 HSD11B1 (0.44) KMT2ANPC1POLBRAB9AMEN1
SCHEMBL5214961 0.75 BACE1 (0.37) KMT2ANPC1LMNAPOLBRAB9A
SCHEMBL7654215 0.74 NAPRT (0.61) NAPRTPRKCIMKNK1MKNK2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275954-A1 Novel Fused Heterocycles and Uses Thereof ASTRAZENECA AB (SE) 2007-11-29 US disclosed
EP-1751119-A1 NOVEL FUSED HETEROCYCLES AND USES THEREOF AstraZeneca AB (SE) 2007-02-14 EP disclosed
WO-2005111001-A1 NOVEL FUSED HETEROCYCLES AND USES THEREOF ASTRAZENECA AB (SE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275954-A1 Novel Fused Heterocycles and Uses Thereof VIP, CCKBR, HRH2 NAPRT 1023/4885KMT2A 3978/4885PRKCI 3576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.